Cadonilimab for recurrent small cell neuroendocrine carcinoma of the cervix: a phase 2 study.
Testing a dual immune-checkpoint drug in rare cervical cancer provided clear safety data and guides future combination strategies for this aggressive subtype.
This phase 2 single-arm trial at MD Anderson tested cadonilimab (bispecific anti-PD-1/CTLA-4 antibody) in 9 patients with recurrent/metastatic small cell neuroendocrine cervical cancer, a rare and aggressive subtype with no established second-line standard. Despite acceptable safety with no grade 4-5 adverse events, the study demonstrated no objective responses and a median PFS of 2.19 months, providing critical evidence that single-agent dual checkpoint blockade is insufficient for this histology and informing future combination strategies.
What the study was
- Study design
- Phase 2 single-arm open-label trial
- Population
- 9 patients with recurrent or metastatic high-grade small cell neuroendocrine cervical cancer (SCNCC); MD Anderson Cancer Center
- Sample size
- 9
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- International Journal of Gynecological Cancer
Why it surfaced
First prospective phase 2 data for bispecific PD-1/CTLA-4 blockade in an ultra-rare aggressive gynecologic cancer with no established salvage therapy; informative negative result establishing baseline for future combination approaches.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.